The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys

Journal of Neural Transmission

Volumn 113, Issue 1, 2006, Pages 11-19

  Brandt Christensen, M ^a   Andersen, M B ^a,c   Fink Jensen, A ^b   Werge, T ^a   Gerlach, J ^a  

^a Sct Hans Hospital   (Denmark)

^b Rigshospitalet   (Denmark)

^c NONE   (Denmark)

Author keywords

( ) OSU6162; Amphetamine; Apomorphine; Cebus; D2 antagonist; Monkey; Psychosis

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; AMPHETAMINE; APOMORPHINE;

ANIMAL EXPERIMENT; AROUSAL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYSTONIA; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY;

AMPHETAMINE; ANIMALS; APOMORPHINE; CEBUS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERIDINES; STEREOTYPED BEHAVIOR;

EID: 29244459436     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0297-1     Document Type: Article

References (37)

1. J Arnt 1995 Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 283 55 62
2. Arnt J (2000) Screening models for antipsychotic drugs. In: Ellenbroek BA, Cools AR, Parnham MJ (eds) Atypical antipsychotics. Birkhäuser, Basel (Milestones in Drug Therapy)
3. LA Arvanitis BG Miller 1997 Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42 233 246
4. KD Burris TF Molski C Xu E Ryan K Tottori T Kikuchi FD Yocca PB Molinoff 2002 Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 381 389
5. A Carlsson 2001 A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel lecture). Chembiochem 2 484 493
6. A Carlsson N Waters S Holm-Waters J Tedroff M Nilsson ML Carlsson 2001 Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41 237 260
7. A Ekesbo PE Andren LM Gunne J Tedroff 1997 (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport 8 2567 2570
8. Ellenbroek B, Cools AR (2002) Animal models for schizophrenia. In: Ellenbroek BA, Cools AR, Parnham MJ (eds) Atypical antipsychotics. Birkhäuser, Basel, pp 565-580 (Milestones in Drug Therapy)
9. A Fink-Jensen EB Nielsen L Hansen MA Scheideler 1998 Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI. Eur J Pharmacol 342 153 161
10. O Gefvert LH Lindström O Dahlbäck C Sonesson N Waters A Carlsson J Tedroff 2000 (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled study. Nordic J Psychiatr 54 93 94
11. J Gerlach DE Casey 1990 Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 14 103 112
12. A Hadj Tahar A Ekesbo L Gregoire E Bangassoro KA Svensson J Tedroff PJ Bedard 2001 Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur J Pharmacol 412 247 254
13. S Jordan V Koprivica R Dunn K Tottori T Kikuchi CA Altar 2004 In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483 45 53
14. JM Kane WH Carson AR Saha RD [tmp] McQuade GG Ingenito DL Zimbroff MW Ali 2002 Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Clin Psychiatry 63 763 771
15. PE Keck Jr SL [tmp] McElroy 2003 Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Invest Drugs 12 655 662
16. T Kikuchi K Tottori Y Uwahodo T Hirose T Miwa Y Oshiro S Morita 1995 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 4 329 336
17. AC Lahti MA Weiler PK Corey RA Lahti A Carlsson CA Tamminga 1998 Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine-(preclamol) in schizophrenia. Biol Psychiatry 43 2 11
18. RA Lahti LM Figur MF Piercey PL Ruppel DL Evans 1992 Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 42 432 438
19. H Lublin 1995 Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia. Clin Neuropharmacol 18 533 551
20. H Lublin J Gerlach L Peacock 1992 Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia. Clin Neuropharmacol 15 448 458
21. H Lublin J Gerlach F Morkeberg 1994 Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Psychopharmacology 114 495 504
22. SR Marder RD [tmp] McQuade E Stock S Kaplita R Marcus AZ Safferman A Saha M Ali T Iwamoto 2003 Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61 123 136
23. V Ozdemir J Fourie F Ozdener 2002 Aripiprazole (Otsuka Pharmaceutical Co). Curr Opin Invest Drugs 3 113 120
24. L Peacock J Gerlach 1993 Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. Eur J Pharmacol 237 329 340
25. L Peacock J Gerlach 1999 New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology 144 189 197
26. L Peacock H Lublin J Gerlach 1990 The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186 49 59
27. L Peacock L Hansen F Morkeberg J Gerlach 1999 Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects. Neuropsychopharmacology 20 35 43
28. UJ Povlsen U Noring AL Laursen S Korsgaard J Gerlach 1986 Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 9 84 90
29. C Sonesson N Waters K Svensson A Carlsson MW Smith MF Piercey E Meier H Wikstrom 1993 Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J Med Chem 36 3188 3196
30. C Sonesson CH Lin L Hansson N Waters K Svensson A Carlsson MW Smith H Wikstrom 1994 Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 37 2735 2753
31. SM Stahl 2001a Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1. "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 62 841 842
32. SM Stahl 2001b Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2. Illustrating their mechanism of action. J Clin Psychiatry 62 923 924
33. CA Tamminga 2002 Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109 411 420
34. CA Tamminga A Carlsson 2002 Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Target CNS Neurol Disord 1 141 147
35. J Tedroff R Torstenson P Hartvig C Sonesson N Waters A Carlsson H Neu KJ Fasth B Langstrom 1998 Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse 28 280 287
36. J Tedroff A Ekesbo C Sonesson N Waters A Carlsson 1999 Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurol 53 1605 1606
37. N Waters K Svensson SR Haadsma-Svensson MW Smith A Carlsson 1993 The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm (Gen Sect) 94 11 19